Navigation Links
HIV drug resistance increasing in UK and among highest in the world

Those infected with HIV in the UK have one of the highest rates of resistance to anti-HIV drugs of anywhere in the world, prompting fears of a second wave epidemic of resistant virus, a new study claims in this week's BMJ.

The study authors are concerned that the large reductions in deaths and improvements to health since people with HIV were given combinations of drugs (combination antiretroviral therapy) may be compromised because of this.

Using national data on HIV positive cases, the researchers tested patients for resistance to the antiretroviral drugs before embarking on the treatment. Tests were conducted on 2,357 patients between 1996 and 2003 ?thus researchers could track if there were changes to resistance patterns as time went on.

They found that 335 people showed some degree of resistance to one or more antiretroviral drugs in total. Most of these people ?257 ?were resistant to drugs within one class only, 44 cases showed resistance to drugs within two classes and 34 showed resistance to drugs within all three commonly used drug classes.

Overall, this equates to a 14% rate of resistance to one or more of these drugs among the group studied over the whole time period. The resistance had reached an estimated 19% for the most recent time period of 2002-2003.

The UK's 14% rate of resistance was considerably higher than the 7% estimate for chronically infected patients in the USA, 6% in France and 10% elsewhere in Europe. Direct comparisons should be treated cautiously, however, as different studies have used different definitions of resistance. Using a more conservative definition of resistance (high level resistance to at least one drug) gives an overall estimate of 9% for the UK for the years 1996-2003, with the rate being 12% in 2002-3.

The authors say: 'The United Kingdom has among the highest reported rates of primary resistance to HIV drugs worldwide. By limiting the therapeutic options for a significant number of patients, the secondary epidemic of drug resistant HIV represents a major clinical and public health problem.'


'"/>

Source:BMJ-British Medical Journal


Related biology news :

1. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
2. Researchers make gains in understanding antibiotic resistance
3. MUHC scientists describe genetic resistance to rampant virus
4. New polysaccharide may help combat multidrug resistance in cancer
5. New book explains antibiotic resistance for a broad audience
6. Insects develop resistance to engineered crops
7. Retroviral resistance gene found
8. Drug resistance testing in treatment-naive HIV patients is cost-effective
9. Researchers use RNAi libraries to identify regulators of apoptosis and chemoresistance
10. Gaining ground in the race against antibiotic resistance
11. Genes linked to treatment resistance in children with leukemia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... PLAINVIEW, N.Y. , Jan. 18, 2017 ... pathology services, announces the formation of an Executive Committee ... 2017 and beyond. John Cucci , ... been promoted from Director of Business Development to ... in 2015, Mr. Cucci served in senior sales leadership ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on ... Valley Stream, NY. The procedure was an anterior cervical discectomy and fusion on ...
(Date:1/18/2017)... ... January 18, 2017 , ... Researchers from a new study are stating that ... enough after prostate cancer treatment, this indicates there is still remaining prostate cancer cells that ... “ The PSA test has always been an indicator of whether a man’s prostate cancer ...
Breaking Biology Technology: